Resource Center
FOR PHARMCEUTICAL MANUFACTURERS
Mastering Best Practices: Vetting Previously Marketed Pharmaceutical Drug Acquisitions
MASTERING BEST PRACTICES: Vetting Previously Marketed Pharmaceutical Drug AcquisitionsPharmaceutical manufacturers considering the acquisition of pre-existing drugs face the challenge of conducting a meticulous and comprehensive analysis across a spectrum of...
The 2024 Medicaid AMP Cap Removal: What Pharma Manufacturers Need to Know
2024 AMP CAP REMOVAL What You Need To Know2024 AMP CAP REMOVAL – WHAT PHARMA MANUFACTURERS NEED TO KNOWThe 2024 Medicaid AMP cap removal will be effective January 1st, 2024, and may have sweeping impacts for drug manufacturers participating in the Medicaid program....
2023 Drug Wastage Rule to Impact Pharma Manufacturers
2023 DRUG WASTAGE RULE TO IMPACTPHARMA MANUFACTURERSPharmaceutical manufacturers continue to experience regulatory and program changes that result in new rebates and/or penalties which have the potential to negatively impact profitability. Last year, the Inflation...
CMS Enforcement for ASP in Medicare Part B
CMS Enforcement of Average Sales Price (ASP) Submissions for all Medicare Part B Eligible Pharmaceuticals and BiopharmaceuticalsRecently, CMS has been sending letters to pharma and biopharma manufacturers (with and without MDRP agreements) indicating that they believe...
Update 2023 Best Price Accumulator Adjustment Program Ruling
Update – 2023 Best Price & Accumulator Adjustment Program Ruling2023 was shaping up to be a year of challenging decisions for manufacturers and restricted access to critical pharmaceuticals for patients. The 2023 implementation of the proposed CMS Medicaid Best...
Inflation Reduction Act Likely To Have A Negative Financial Impact On Many Drug Manufacturers
Inflation Reduction Act Likely to Have a Negative Financial Impact On Many Drug ManufacturersOn August 16, 2022, the Inflation Reduction Act of 2022 was signed into law with provisions aimed at lowering drug, health care and energy costs for consumers in the United...
Letting Some Air Out of the AMP Inflation Penalty
Letting some air out of the AMP inflation penalty.As of late, we have all been bombarded by headlines lamenting or explaining the recent high inflation rates as we consume our daily news. The default reaction to rising inflation is typically in relation to rising...
Three Things To Know About The Challenges of VA/FSS Contracting
Three things to know about the challenges of VA/FSS contracting.The Veterans/Federal Supply Schedule (VA/FSS) is likely the most complex and time-consuming government contracting process you will face. Public Law 102-585 requires brand manufacturers to participate in...
Understanding Baseline AMP Rules Can Help You Avoid Pricing Decision Disasters
Understanding Baseline AMP Rules Can Help You Avoid Pricing Decision DisastersWhat brand and generic drug manufacturers need to knowA lack of understanding respective to baseline Average Manufacturer Price (AMP) and how it can affect your Medicaid pricing can result...
Professor Jeremy’s
KEY TERMS
FOR PHARMA EXECUTIVES
Pharmaceutical professionals often face challenges with the industry’s language, acronyms, and key players. This glossary offers an overview of essential terms every executive should know.